Impact of 4% t-EDTA on Catheter Occlusions and Bloodstream Infections in Critical Care Cohorts

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  JAMA. https://doi.org/10.1001/jama.2026.6025 
Dr. Marlena Ornowska et al.

Points

A triple-blind multicenter clinical trial demonstrates that utilizing a four percent tetrasodium EDTA catheter lock solution significantly reduces central venous access line complications among critically ill patients.
The large investigation tracked one thousand four hundred sixty-eight adult intensive care unit patients across six Canadian hospitals to compare standard line care with the experimental locking solution.
Clinical data showed that the primary composite outcome rate dropped from nineteen point nine to thirteen point one events per one thousand catheter-days when using the intervention.
The adjusted statistical analysis revealed a thirty-two percent overall reduction in complications which was driven primarily by fewer catheter occlusions requiring corrective alteplase thrombolytic treatments.
Safety monitoring confirmed that the tetrasodium EDTA solution caused no adverse events or chemical imbalances like hypocalcemia during the multi-center critical care evaluation period.

Summary

This study evaluated the efficacy and safety of utilizing a 4% tetrasodium ethylenediaminetetraacetic acid (t-EDTA) catheter locking solution to reduce central venous access device (CVAD) complications in critically ill patients. Conducted as a triple-blind, multicenter, cluster-randomized crossover trial across six Canadian intensive care units (ICUs), the CLiCK trial enrolled 1,468 adult patients. The primary objective was to determine if instilling this potent anticoagulant, antimicrobial, and antibiofilm agent into inactive lumens could mitigate catheter-associated bloodstream infections, catheter occlusions, and premature line removals compared to standard usual care.

Hemodynamic and operational data revealed that the primary composite outcome occurred at a rate of 13.1 events per 1,000 catheter-days in the 4% t-EDTA treatment group compared to 19.9 events per 1,000 catheter-days in the control group. In the adjusted multi-variable analysis, this represented a statistically significant 32% reduction in the overall rate of CVAD complications. The therapeutic benefit was driven most clearly by a substantial decrease in the frequency of catheter occlusions requiring the administration of alteplase thrombolytic therapy or demanding structural line removal due to lumen blockage.

Safety profiles indicated excellent systemic tolerability for the 4% t-EDTA lock solution within complex, busy critical care environments. No adverse events, serious adverse events, or secondary metabolic complications such as hypocalcemia were reported in association with the study locking fluid during the intervention period. The findings suggest that 4% t-EDTA is a highly viable and safe therapeutic strategy to maintain central line patency and decrease infection risk, offering clinicians robust peer-reviewed evidence to improve standard central venous access management guidelines worldwide.

Link to the article: https://jamanetwork.com/journals/jama/fullarticle/2849321#google_vignette

References

Ornowska, M., Wittmann, J., Blitz, S., Wong, H., Vazquez-Grande, G., Mitra, A. R., Jang, W., Wood, G., Ovakim, D., Forrest, D., Rohrs, E., & Reynolds, S. (2026). 4% tetrasodium edta to prevent central venous access device–associated complications: A randomized clinical trial. JAMA. https://doi.org/10.1001/jama.2026.6025